1. Jiang L, Wang J, Wang Y, Yang H, Kong L, Wu Z, Shen A, Huang Z, Jiang Y. Bibliometric and LDA analysis of acute rejection in liver transplantation: Emerging trends, immunotherapy challenges, and the role of artificial intelligence. Cell Transplant. 2025 Jan-Dec;34:9636897251325628. (Correspondence author)
2. Xu Q, Li X, Yuan Y, Hu Z, Zhang W, Wang Y, Shen A, Lei H. Development and validation of a nomogram model for predicting immune-mediated hepatitis in cancer patients treated with immune checkpoint inhibitors. Biosci Trends. 2025 May 9;19(2):202-210.(Correspondence author)
3. Xu P, Liu M, Liu M, Shen A. Management of non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Biosci Trends. 2024 Nov 15;18(5):431-443.(Correspondence author)
4. Kong L, Liu M, Yang H, Yan P, Luo Y, Xiang S, Huang Z, Shen A. Expression of copper metabolism-related genes is associated with the tumor immune microenvironment and predicts the prognosis of hepatocellular carcinoma. Transl Cancer Res. 2024 May 31;13(5):2251-2265. (Correspondence author)
5. 孔令旺,沈艾.RNA m6A甲基化修饰及其在肝癌中的作用.医学新视角. 2024;1(2):82-88. (Correspondence author)
6. Liu M, Shen A. Considerations on 'Comparison of short-term outcomes between robotic and laparoscopic liver resection: a meta-analysis of propensity score-matched studies'. Int J Surg. 2024 Jul 1;110(7):4445-4446. (Correspondence author)
7. Liu M, Shen A, Pang H. Considerations regarding a meta-analysis of laparoscopic total gastrectomy vs. laparoscopic-assisted total gastrectomy for gastric cancer. Int J Surg. 2024 Mar 1;110(3):1853-1854. (Co-first author)
8. Liu M, Shen A, Zheng Y, Chen X, Wang L, Li T, Ouyang X, Yu X, Sun H, Wu X. Long non-coding RNA lncHUPC1 induced by FOXA1 promotes tumor progression by inhibiting apoptosis via miR-133b/SDCCAG3 in prostate cancer. Am J Cancer Res. 2022 Jun 15;12(6):2465-2491. (Co-first author)
9. Chen QS, Shen A, Dai JW, Li TT, Huang WF, Shi K, Deng Y, Pan L, Wei XF, Wu ZJ. IL37 overexpression inhibits autophagy and apoptosis induced by hepatic ischemia reperfusion injury via modulating AMPK/mTOR/ULLK1 signalling pathways. Life Sci. 2021 Jul 1;276:119424. (Co-first author)
10. Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020.(Correspondence author)
11. Shen A, Zheng D, Luo Y, Mou T, Chen Q, Huang Z, et al. MicroRNA-24-3p alleviates hepatic ischemia and reperfusion injury in mice through the repression of STING signaling. Biochem Biophys Res Commun. 2020; 522: 47-52.(First author)
12. Shi J, Shen A, Mou T, Wu, Z. Treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Journal of Cancer Therapy. 2020; 11, 115-123. (Co-first author)
13. Shen A, Liu M, Zheng D, Chen Q, Wu Z. Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):142-154. (First author)
14. Shen A,Liu S,Yu W,Deng H,Li Q,p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study, J Gastroenterol Hepatol, 2015.11.01,30(11)：1651-1656 (First author)
15. Tang C,Shen A,Wei X,Li Q,Liu R,Deng H,Wu Y,Wu Z,Everolimus in de novo liver transplant recipients: a systematic review,Hepatobiliary & Pancreatic Diseases International, 2015.10.15, 14(5)：461-469 (Co-first author)
16. Shen A,Zhang H,Tang C,Chen Y,Wang Y,Zhang C,Wu Z,Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm,J Gastroenterol Hepatol,2013.5.01,28(5)：793-800 (First author)
17. Shen A,Tang C,Wang Y,Chen Y,Yan X,Zhang C,Liu R,Wei X,Zhu Y,Zhang H,Wu Z,A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma,J Clin Gastroenterol,2013.01.01,47(10)：871-880 (First author)
二、承担和参与的科学研究项目
主持项目
1.重庆市中青年医学高端人才培养经费，2024005,2024/07-现在，50万元，在研，主持
2.重庆市科卫联合科研项目, 2023MSXM104, HAILC联合仑伐替尼治疗合并门静脉癌栓的肝癌的临床研究, 2023/01-2024/12, 16万元, 已结题, 主持
3.中央高校基本科研项目自科专项，2021CDJYGRH-015，新型环境污染物诱导肝癌的机制及早期响应指标，2021/07-2023/06，30万，已结题，主持
4.重庆市重点实验室开放基金，ATG5依赖的自噬抑制STING-TBK1诱导的细胞焦亡减轻肝脏缺血再灌注损伤的机制研究，2022/01-2023/12，20万，已结题，主持
5.重庆市科委技术创新与应用示范(社会民生类)项目，cstc2019jscx-msxm0144，术中腹腔热灌注化疗应用于可切除胰腺癌的临床研究，2019/07-2022/09，20万，已结题，主持
6.重庆市自然科学基金，cstc2018jcyjAX0800，IL-37通过IL-18Rα及IL-1R8抑制肝细胞性肝癌细胞增殖和侵袭的机制研究，2018/07-2021/06，10万，已结题，主持
参与项目
1. 国家自然科学基金面上项目,No.52370199,纳米塑料与微囊藻毒素的交互作用及其对人体肝细胞的毒性机制,2024-01至今,58万元,在研,参与
2. 重庆市科技局,科研机构绩效激励引导专项, cstc2022jxjl0065, TRIM37介导IKKγ胞质转位促进细胞焦亡在肝缺血再灌注损伤中的机制研究, 2023-01 至 今, 10万元, 在研, 参与
3. 中央高校基本科研业务费, 自主布局, 2022CDJYGRH-008, 炎症人群肠道抗生素抗性基因特征及其在城市排水系统的迁移规律, 2022-09 至 今, 25万元, 在研, 参与
4. 重庆市卫计委及重庆市科技局,科卫联合技术创新与应用发展项目,2020MSXM071,肝动脉化疗栓塞术联合TOMO治疗原发性肝癌下腔静脉、右心房癌栓临床研究,2020/09-至今,10万,已结题,参与
5. 重庆市科委技术创新与应用示范(社会民生类)项目,cstc2018jscx-msyb0156,术后应用顺铂联合多西紫杉醇的腹腔热灌注化疗治疗进展期胃癌的临床研究和推广,2018/07-2020/06,10万,已结题,参与
6. 重庆市科委应用开发(一般)项目,cstc2013yykfA0093,术后辅助应用索拉菲尼治疗乙型肝炎病毒相关性肝癌的有效性和安全性研究,2014/01-2015/12,80万元,已结题,参与
7. 国家自然科学基金面上项目,No.81270559,Tim3/Galectin-9途径在大鼠肝移植免疫耐受诱导中的作用及机制,2013/01-2016/12,70万,已结题,参与
发明专利
1. 获批国家发明专利一项,ZL201811003698.7,一种用于肝胆外科的可视超声刀以及远程超声手术系统(沈艾、刘苗、叶敏),2019.05.21
三、相关奖励与荣誉
